Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $213

Benzinga · 08/03 14:06
Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $213.